{
    "id": 25316,
    "fullName": "MCL1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MCL1 positive indicates the presence of the MCL1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4170,
        "geneSymbol": "MCL1",
        "terms": [
            "MCL1",
            "bcl2-L-3",
            "BCL2L3",
            "EAT",
            "Mcl-1",
            "MCL1-ES",
            "mcl1/EAT",
            "MCL1L",
            "MCL1S",
            "TM"
        ]
    },
    "variant": "positive",
    "createDate": "09/08/2016",
    "updateDate": "12/04/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9015,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S63845 potently inhibited survival of MCL1-positive acute myeloid leukemia cell lines in culture, and induced complete remission in cell line xenograft models (PMID: 27760111).",
            "molecularProfile": {
                "id": 26203,
                "profileName": "MCL1 positive"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19073,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VU661013 treatment of an MCL1-positive acute myeloid leukemia cell line resulted in decreased growth in culture and reduced tumor burden and increased survival in xenograft models, and led to growth inhibition of a Venclexta (venetoclax)-resistant cell line in culture (PMID: 30185627).",
            "molecularProfile": {
                "id": 26203,
                "profileName": "MCL1 positive"
            },
            "therapy": {
                "id": 8904,
                "therapyName": "VU661013",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16724,
                    "pubMedId": 30185627,
                    "title": "A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20152,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VU661013 treatment induced apoptosis and inhibited growth of estrogen receptor-positive breast cancer cell lines expressing MCL1 in culture, and induced cell death and inhibited tumor growth in a cell line xenograft model (PMID: 31595181).",
            "molecularProfile": {
                "id": 26203,
                "profileName": "MCL1 positive"
            },
            "therapy": {
                "id": 8904,
                "therapyName": "VU661013",
                "synonyms": null
            },
            "indication": {
                "id": 60076,
                "name": "estrogen-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16725,
                    "pubMedId": 31595181,
                    "title": "Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31595181"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9180,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) decreased MCL1 and XIAP expression level, inhibited growth of head and neck squamous cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 26124202).",
            "molecularProfile": {
                "id": 26203,
                "profileName": "MCL1 positive"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6993,
                    "pubMedId": 26124202,
                    "title": "Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26124202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9008,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S63845 potently inhibited survival of MCL1-dependent multiple myeloma cell lines in culture, and induced tumor regression in cell line xenograft models (PMID: 27760111).",
            "molecularProfile": {
                "id": 26203,
                "profileName": "MCL1 positive"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9181,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) and Platinol (cisplatin) synergistically decreased MCL1 and XIAP expression level, inhibited growth of head and neck squamous cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 26124202).",
            "molecularProfile": {
                "id": 26203,
                "profileName": "MCL1 positive"
            },
            "therapy": {
                "id": 1725,
                "therapyName": "Adavosertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6993,
                    "pubMedId": 26124202,
                    "title": "Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26124202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9836,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Nexavar (sorafenib) and quinacrine demonstrated synergy in decreasing viability of MCL1-expressing anaplastic thyroid cancer cell lines in culture, and improved survival in an orthotopic cell line xenograft model of MCL1-expressing anaplastic thyroid cancer (PMID: 27307592).",
            "molecularProfile": {
                "id": 26203,
                "profileName": "MCL1 positive"
            },
            "therapy": {
                "id": 1720,
                "therapyName": "Quinacrine + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7661,
                    "pubMedId": 27307592,
                    "title": "Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8242,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Cytosar-U (cytarabine) combination treatment synergistically induced apoptosis in Mcl1 positive acute myeloid leukemia cells in culture (PMID: 27103402).",
            "molecularProfile": {
                "id": 26203,
                "profileName": "MCL1 positive"
            },
            "therapy": {
                "id": 3182,
                "therapyName": "Cytarabine + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6583,
                    "pubMedId": 27103402,
                    "title": "Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103402"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8239,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Daunorubicin combination treatment reduced Bcl2 and Mcl1 association with Bcl2l11 (Bim), resulted in enhanced cytotoxicity in acute myeloid leukemia cells in culture (PMID: 27103402).",
            "molecularProfile": {
                "id": 26205,
                "profileName": "BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4669,
                "therapyName": "Daunorubicin + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6583,
                    "pubMedId": 27103402,
                    "title": "Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103402"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19075,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VU661013 and Venclexta (venetoclax) combination therapy reduced tumor burden and increased survival (p=0.003) in cell line xenograft models of MCL1 and BCL2-positive acute myeloid leukemia, and led to growth inhibition of a Venclexta (venetoclax)-resistant cell line and synergistic effects against VU661013-resistant cells in culture (PMID: 30185627).",
            "molecularProfile": {
                "id": 26205,
                "profileName": "BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 8905,
                "therapyName": "Venetoclax + VU661013",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16724,
                    "pubMedId": 30185627,
                    "title": "A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19074,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) treatment inhibited growth of a BCL2 and MCL1-positive acute myeloid leukemia cell line resistant to VU661013 in culture (PMID: 30185627).",
            "molecularProfile": {
                "id": 26205,
                "profileName": "BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16724,
                    "pubMedId": 30185627,
                    "title": "A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9058,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute lymphocytic leukemia cells dependent with low Bcl2/Mcl1 ratio demonstrated minimal sensitivity to Venclexta (venetoclax) in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26205,
                "profileName": "BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9068,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Gleevec (imatinib) synergistically inhibited growth and induced apoptosis in Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4867,
                "therapyName": "Imatinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9069,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically inhibited growth and induced apoptosis in Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9071,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Sprycel (dasatinib) synergistically inhibited growth and induced apoptosis in patient-derived, Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture, resulted in tumor inhibition in patient-derived xenograft models (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4868,
                "therapyName": "Dasatinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9070,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Iclusig (ponatinib) synergistically inhibited growth and induced apoptosis in Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4869,
                "therapyName": "Ponatinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9066,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) inhibited growth and induced apoptosis in both patient-derived and established Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9571,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cotellic (cobimetinib) treatment in culture resulted in down regulation of MCL1 expression, but only moderately induced apoptotic activity in a colorectal cancer cell line harboring BRAF V600E compared to BRAF wild-type colorectal cancer cell lines (PMID: 27765849).",
            "molecularProfile": {
                "id": 26906,
                "profileName": "BRAF V600E MCL1 pos"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7284,
                    "pubMedId": 27765849,
                    "title": "Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765849"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9572,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-1210477 demonstrated a synergistic effect when combined with Cotellic (cobimetinib), resulting in decreased expression of MCL1 and increased apoptotic activity in colorectal cancer cells harboring BRAF V600E in culture (PMID: 27765849).",
            "molecularProfile": {
                "id": 26906,
                "profileName": "BRAF V600E MCL1 pos"
            },
            "therapy": {
                "id": 5091,
                "therapyName": "A-1210477 + Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7284,
                    "pubMedId": 27765849,
                    "title": "Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9578,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Zelboraf (vemurafenib) to the combination of A-1210477 and Cotellic (cobimetinib) did not result in greater apoptotic activity in colorectal cancer cell lines expressing MCL1 and harboring BRAF V600E in culture (PMID: 27765849).",
            "molecularProfile": {
                "id": 26906,
                "profileName": "BRAF V600E MCL1 pos"
            },
            "therapy": {
                "id": 5093,
                "therapyName": "A-1210477 + Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7284,
                    "pubMedId": 27765849,
                    "title": "Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9576,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of A-1210477 and Zelboraf (vemurafenib) compared to A-1210477 combined with Cotellic (cobimetinib) resulted in decreased apoptotic activity in colorectal cancer cells expressing MCL1 and harboring BRAF V600E in culture (PMID: 27765849).",
            "molecularProfile": {
                "id": 26906,
                "profileName": "BRAF V600E MCL1 pos"
            },
            "therapy": {
                "id": 5092,
                "therapyName": "A-1210477 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7284,
                    "pubMedId": 27765849,
                    "title": "Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765849"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9575,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-1210477 treatment compared to the combination treatment of A-1210477 and Cotellic (cobimetinib) resulted in decreased apoptotic activity in colorectal cancer cells expressing MCL1 and harboring BRAF V600E in culture (PMID: 27765849).",
            "molecularProfile": {
                "id": 26906,
                "profileName": "BRAF V600E MCL1 pos"
            },
            "therapy": {
                "id": 3276,
                "therapyName": "A-1210477",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7284,
                    "pubMedId": 27765849,
                    "title": "Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765849"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9573,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-1210477 demonstrated a synergistic effect when combined with Cotellic (cobimetinib), resulting in decreased expression of MCL1 and increased apoptotic activity in melanoma cells harboring BRAF V600E in culture (PMID: 27765849).",
            "molecularProfile": {
                "id": 26906,
                "profileName": "BRAF V600E MCL1 pos"
            },
            "therapy": {
                "id": 5091,
                "therapyName": "A-1210477 + Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7284,
                    "pubMedId": 27765849,
                    "title": "Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10135,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with PTC596 in acute myeloid leukemia cells expressing BMI1 and MCL1 resulted in mitochondrial induced apoptotic activity and decreased expression of MCL1 in culture (PMID: 28211885).",
            "molecularProfile": {
                "id": 27300,
                "profileName": "BMI1 pos MCL1 pos"
            },
            "therapy": {
                "id": 5407,
                "therapyName": "PTC596",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8142,
                    "pubMedId": 28211885,
                    "title": "The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28211885"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19076,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and VU661013 combination therapy induced apoptosis and reduced tumor burden in a patient-derived xenograft (PDX) model of MCL1-positive and BCL2-dependent disseminated acute myeloid leukemia, however, did not exhibit synergistic effects compared to Venclexta (venetoclax) treatment (PMID: 30185627).",
            "molecularProfile": {
                "id": 33893,
                "profileName": "BCL2 over exp MCL1 pos"
            },
            "therapy": {
                "id": 8905,
                "therapyName": "Venetoclax + VU661013",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16724,
                    "pubMedId": 30185627,
                    "title": "A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20153,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VU661013 and Navitoclax (ABT-263) combination treatment induced apoptosis and inhibited growth of estrogen receptor-positive breast cancer cell lines expressing BCL2, BCL2L1, and MCL1 in culture, and induced cell death and inhibited tumor growth in a cell line xenograft model (PMID: 31595181).",
            "molecularProfile": {
                "id": 34907,
                "profileName": "BCL2 pos BCL2L1 pos MCL1 pos"
            },
            "therapy": {
                "id": 9280,
                "therapyName": "Navitoclax + VU661013",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16725,
                    "pubMedId": 31595181,
                    "title": "Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31595181"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26203,
            "profileName": "MCL1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26205,
            "profileName": "BCL2 pos MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26700,
            "profileName": "BCR - ABL1 BCL2 pos MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26906,
            "profileName": "BRAF V600E MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27300,
            "profileName": "BMI1 pos MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33893,
            "profileName": "BCL2 over exp MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34511,
            "profileName": "BCL2 pos FLT3 exon 14 ins MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34907,
            "profileName": "BCL2 pos BCL2L1 pos MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}